Introduction {#S5}
============

Survival with Human Immunodeficiency Virus (HIV) infection has been extended because of antiretroviral therapies (ART). Thus, HIV infection is becoming a chronic infection of aging, along with other aging-related conditions, such as Type 2 diabetes (T2D), cardiovascular diseases, and cognitive impairments. In many countries, the advent of ART has been accompanied by an increase in body mass index (BMI) that mirrors trends in the general population. Thus individuals with HIV infection are becoming more overweight and obese, which increases their risk for developing the aforementioned leading causes of disability and death in the United States and around the world, particularly of interest here, cognitive impairments \[[@R1]--[@R3]\].

The gut brain axis has been extensively implicated in human health. Hormones secreted by the gut have been shown to interact with the brain and regulate feeding behavior and energy balance \[[@R4]\]. Food intake behavior and energy homeostasis are strongly regulated by a complex system of humoral factors and neural structures constituting the gut-brain axis. To date, the only known peripherally produced and centrally acting peptide that stimulates food intake (orexigenic) is ghrelin, which is mainly synthesized in the stomach.

Ghrelin, discovered by Japanese researchers in 1999, is an orexigenic polypeptide (i.e., it stimulates the appetite and increases dietary intake), composed of 28 amino acids, and is secreted mainly by the P/DI cells lining the stomach fundus and, to a lesser degree, by various organs: intestine, pancreas, kidney, hypothalamus, and pituitary gland \[[@R5],[@R6]\]. Ghrelin secretion increases under fasting conditions and falls after food intake. After gastrectomy, the concentration of ghrelin in plasma falls approximately 75%, which shows the importance of its secretion by the stomach \[[@R7],[@R8]\].

Ghrelin may interact with leptin, which induces satiety at high levels, to regulate energy balance. Ghrelin is an example of the neurochemical overlap between reward and energy balance regulation systems, and the reward systems have been implicated in addictive behaviors such as compulsive overeating and drug dependence \[[@R9],[@R10]\]. Ghrelin also appears to activate the cholinergic-dopaminergic reward link, which is associated with reward and motivated behavior, such as food searching. In the brain, ghrelin is produced by the arcuate nucleus and stimulates secretion of HGH from the anterior pituitary \[[@R7]\]. Ghrelin also acts on the level of the hypothalamus by stimulating biosynthesis and secretion of neuropeptide Y and Agouti-Related Protein \[[@R5],[@R11]\]. Polymorphisms in the pro-ghrelin gene have been associated with obesity \[[@R10]\] and methamphetamine dependence, while polymorphisms in the ghrelin receptor gene have been associated with bulimia \[[@R12]\] and obesity \[[@R7],[@R10],[@R12],[@R13]\].

Amylin, a 37 amino acid peptide, is co-secreted with insulin by pancreatic beta cells, either in response to glucose or sulfonylureas stimulation \[[@R14]\]. This is in contrast to ghrelin secretion, described above. Amylin, which is deficient in those with T2D, inhibits glucagon secretion, delays gastric emptying, and promotes satiety, thereby decreasing postprandial blood glucose \[[@R15]--[@R17]\]. Plasma amylin is positively associated with cognitive function \[[@R18]--[@R20]\]. Amylin treatment improves memory in AD mouse models \[[@R19]\]. However, amylin's activities in cognition are impaired in the presence of T2D \[[@R20]\].

Gastric Inhibitory Peptide (GIP), also referred to as Glucose-dependent insulinotropic peptide, is an incretin, an intestinal peptide secreted by the gut in response to dietary intake of glucose, lipids and carbohydrates \[[@R21]\]. Incretins have been suggested to be a key link to obesity and physiological responses to today's obesigenic environments. In fact, analogues of GIP have been developed to treat T2D. Some of these analogues cross the blood-brain barrier, are neuroprotective, activate the brain's neuronal stem cells, and improve cognition. Receptors for GIP are expressed in neurons, and GIP is expressed and released as a transmitter by neurons \[[@R22]\]. GIP analogues such as DAla(2)GIP, enhance synaptic plasticity in the brain and reverse the beta amyloid induced impairment of synaptic plasticity in Alzheimer mouse models \[[@R23]\].

Today, according to PubMed, there are no published reports on the association between GIP and cognition or dementia in adults infected or not with HIV. Studies in mice are equivocal \[[@R24],[@R25]\], however studies of GIP receptor knockout mice show impaired cognition \[[@R26]--[@R28]\]. In contrast, activation of GIP agonists has been shown to improve cognition in mouse models \[[@R29]\].

In the present study, we investigated whether levels of three gut hormones are differentially associated with cognitive performance in middle-aged women who are HIV+ vs HIV− and participate in the Women's Interagency HIV Study (WIHS) \[[@R21],[@R22]\]. Previous analyses in this same group of women have shown that higher levels of BMI and lower levels of blood leptin are associated with better cognitive function \[[@R30],[@R31]\].

Materials and Methods {#S6}
=====================

The WIHS is an ongoing prospective study of HIV infection in women \[[@R32]\]. WIHS began in 1994 and enrolled 3766 women across six sites in San Francisco, Los Angeles, Chicago, Washington, DC, Brooklyn and the Bronx (New York). Across all sites, WIHS initially recruited 2054 HIV infected (HIV+) and 569 at-risk HIV uninfected (HIV−) women in 1994--1995 and an additional 737 HIV-infected and 406-HIV uninfected women in 2001--2002. The Brooklyn WIHS site has participated since the WIHS' inception. Among the Brooklyn participants 356 (247 HIV+, 107 HIV−) had available cognitive tests and gut hormone measures. Written informed consent was provided by all Brooklyn WIHS participants via a human subject's protocol that was approved by the SUNY Downstate Medical Center Institutional Review Board (protocol \# 266921).

Demographic measures {#S7}
--------------------

All demographic measures were self-reported. Race \[[@R32],[@R33]\] was self-reported as white, Hispanic, African-American (AA), or 'other' (e.g., Native American/Alaskan, Asian/Pacific Islander) for all participants. Participants are also asked to report the current socioeconomic status, educational levels attained, smoking status, and use of marijuana, 'crack', cocaine, and heroin.

Clinical measures {#S8}
-----------------

Anthropometric measures were conducted according to the NHANES III protocol, wearing light clothing, and included body weight (pounds), body height (inches), waist and hip circumferences (cm), and BMI (kg/m^2^) \[[@R23]\]. Body weight was recorded to the nearest 1.0 pound, and body height was measured to the nearest 1.0 inch. After conversion of body weight and height to metric units, BMI was calculated as kilograms per meter squared (kg/m^2^). Categories of BMI included ≥ 25 kg/m^2^ for overweight and obesity and ≥ 30 kg/m^2^ for obesity \[[@R34]\]. Waist and hip circumferences were measured to the nearest 0.5 cm. WHR was calculated as the ratio of waist to hip circumference. Central obesity was defined as WHR \>0.80 or WC ≥ 88 cm \[[@R35]\].

Eight hour fasted blood samples were collected and total cholesterol levels were determined as previously described \[[@R26]\]. Systolic (SBP) and diastolic blood pressures (DBP) were recorded using a standardized protocol \[[@R36]\]. Hypertension was defined as either average measured SBP\>140 mm Hg or DBP \>90 mm Hg, self-reported hypertension, or use of antihypertensive medications. Previous myocardial infarction (MI) and T2D were self-reported \[[@R32],[@R33]\].

Biomarker analysis {#S9}
------------------

Plasma samples, standards and controls were tested in duplicate using an active ghrelin ELISA, and active amylin and gastric inhibitory polypeptide (GIP) were measured by Luminex multiplex assay (Millipore, Billerica, MA). For active ghrelin, samples were tested undiluted and plates were prepared according to protocol and quantified using a 6-point standard curve ranging from 172 to 5500 ng/mL. Plates were read using a Molecular Devices Plate reader and Softmax Pro data analysis software. A 5-PL curve fit was used. Data analysis was performed using Softmax Pro 5.0. For amylin and GIP, samples, standards and controls were tested in duplicate and the assay was prepared according to protocol using a 7 point standard curve. Plates were read using the Bioplex 200 with Bioplex Manager (BioRad, Hercules, CA).

HIV-related variables {#S10}
---------------------

Methods for determining HIV status, AIDS diagnosis, CD4 count, viral load, and duration of ART use were described previously \[[@R32],[@R33]\].

Cognitive tests {#S11}
---------------

Cognitive tests (Trails A, Trails B, Stroop interference time, Stroop word recall, Stroop color naming and reading, Symbol Digit Modalities Test (SDMT) and the Wide Range Achievement Test (WRAT) were administered to all English-speaking WIHS participants during visits 21 to 24 (October 2004 to September 2006) as part of the WIHS core assessment; the Comalli-Kaplan Stroop was administered to a subgroup during visits 25--28, October 2006 to September 2008 ([Table 1](#T1){ref-type="table"}). These tests have been previously described \[[@R41]\]. Among participants who completed testing on multiple visits, and therefore have more than one score, only the first score was used. Times greater than 240 s were coded as 240 s, errors were recorded, but were not used to adjust interference times. For all cognitive tests, we used raw scores rather than normalized data.

Inclusion criteria {#S12}
------------------

We include all data collected by visit 28 among all Brooklyn WIHS participants, concluding in September 2008 for 356 participants (247 HIV+, 107 HIV−) with data available on both anthropometric and cognitive measures.

Statistical analysis {#S13}
--------------------

Gut hormones were considered as continuous variables, except for ghrelin. Ghrelin was considered in quintiles due to measurement limits of the assay and one-fifth of samples in the lowest quintile having the same value. Linear regression analyses were used to examine associations between continuous or categorical gut hormones and cognitive test scores (time to completion) of Trails A, Trails B, SDMT score, Stroop interference, Stroop Color Naming, and Stroop Word Recall. Regression models were run separately for infected and uninfected women.

Several covariates were considered including: age, race, highest educational level attained, Wide Range Achievement Test (WRAT) score, HIV status, ART, CD4 count, CD4 nadir, prevalent DM, SBP, DBP, use of anti-hypertensive medications, use of exogenous insulin, blood cholesterol level, current smoking status, and use of marijuana, 'crack', cocaine, and/or heroin. Potential covariates were included if significant in age-adjusted models at a level of *p*\<0.05. Given this significance level, final models included the following covariates: age, WRAT, race, exogenous insulin, use of antiretroviral therapy (ART) and any recreational drug use. Other HIV-related covariates evaluated, such as CD4 count or CD4 nadir, were not included because they were not associated with cognition or the gut hormones. In analyses of women who were HIV+, we also adjusted for HIV viral load. In sensitivity analyses of both HIV+ and HIV− women, we excluded drug users. STATA 12 was used for all statistical analyses. Results were considered statistically significant at *p*\<0.05.

Results {#S14}
=======

Both gut hormone and cognitive measures were available for 356 Brooklyn WIHS participants (213 HIV+ and 97 HIV− women). Demographic, anthropometric, and health characteristics are presented in [Table 2](#T2){ref-type="table"}. Based on average age (mean age 38.9 years), these women were not at risk for late-onset, aging-related cognitive impairments or dementias. HIV+ women were approximately 4 years older than HIV− women, however educational attainment, a key influencer of cognitive performance, did not differ between HIV+ and HIV− women. As previously reported, most participants were overweight or obese (≥ 25.0 kg/m^2^) and the frequency of central obesity was high.

Correlations between anthropometric measures and gut hormones indicated modest associations in the directions expected for ghrelin and amylin ([Table 3](#T3){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Notably the correlation coefficients were positive for anthropometric measures and amylin, and negative for ghrelin. No correlation was observed for GIP and anthropometric measures. In addition, there were lower average levels of amylin, WHR and BMI (*p*\<0.10) among HIV+ women compared to uninfected women WHR was higher among HIV+ women. Neither ghrelin nor GIP was associated with HIV infection status.

Associations between gut hormones and cognitive test scores in linear regression models revealed an inverse association between amylin and Trails A in HIV+ and HIV− participants after multivariate adjustment (Model 2) ([Table 4](#T4){ref-type="table"}). An inverse association was also observed for GIP among HIV+ women. Ghrelin was inversely associated with Trails A and Stroop Color Naming time among HIV− women. Ghrelin was also associated with Stroop Word Reading time in HIV+ women, as was GIP. In summary, higher gut hormone levels were associated with better cognition.

Discussion {#S15}
==========

Among women at mid-life with HIV infection for at least 10 years, or among those at risk, better performance on cognitive tests was generally associated with higher gut hormone levels. However, the strength of association varied, as did significance level by HIV status. To our knowledge, there are no published reports on these gut hormones in association with cognition in HIV-infection.

The importance of understanding the association of gut hormones with cognition, originates from published associations between high BMI and obesity or metabolic syndromes with cognition and dementia among HIV uninfected population samples \[[@R1],[@R43]--[@R45]\]. High mid-life BMI \[[@R2],[@R43],[@R44]\] central obesity (measured as waist circumference or WHR), \[[@R3],[@R45]\] and T2D \[[@R46]\] have been shown to increase risk for Alzheimer's Disease (AD) in uninfected populations. Simple anthropometric measures reflect different aspects of body composition, and, at best, are crude indicators of the body's metabolism in response to energy intake. A high BMI is reasonably correlated with whole body amount of adipose tissue and higher energy intake in healthy HIV-negative adults \[[@R47]\]. Going further to assess gut hormone associations among those with or at risk for HIV infection, may enhance our understanding of mechanisms underlying this association. High BMI and WC during mid-life are also related to other vascular risk factors, such as T2D \[[@R48]\], hypertension, and hyperlipidemia \[[@R49]\], which increase risk for cognitive impairments and dementia in non-HIV populations.

Amylin is interesting for cognitive brain health for several reasons. Potential key roles of amylin in cognition and AD are related to: 1) its co-secretion with insulin from pancreatic beta-cells to regulate postprandial glycemia; 2) its role in the development of T2D (amylin is deficient in T2D); 3) T2D being a risk factor for AD and vascular forms of dementia; and 4) amylin being pancreatic islet amyloid polypeptide (PIAPP), in comparison and contrast to the amyloid precursor protein (APP) that is differentially spliced to form the fragments that form amyloid-beta (Ab) that deposits in the aging brain and has been touted as the underlying neuropathologic molecule responsible for Alzheimer's Disease \[[@R50],[@R51]\]. Some data suggest that amylin may play a vital role at the interface between peripheral and neurodegenerative disorders, and that amylin and Aβ interact in the brain \[[@R51]\]. Evidence to support the latter includes PIAPP being present in human cerebrospinal fluid (CSF), synthetic PIAPP promoting Aβ oligomerization *in vitro* and endogenous IAPP localizing to Aβ oligomers and plaques \[[@R52]\]. While higher levels of blood amylin are associated with higher BMI, lower blood levels of amylin have been observed in adults with more severe forms of cognitive impairment, such as dementia \[[@R18]\]. This is congruent with the low BMI and low leptin levels observed cross-sectionally in those with dementia, and that cognition is enhanced with the amylin analog, pramlintide \[[@R19]\]. Similar to other reports in HIV− samples that relate anthropometric measures to gut hormone levels, our findings demonstrate that higher amylin levels were associated with higher levels of overweight and obesity \[[@R53]\].

Ghrelin may also improve cognition \[[@R54]\]. Executive function and speed of information processing are the cognitive domains most commonly associated with these hormonal measures. Ghrelin plays a role in multiple physiological processes including appetite regulation, metabolism and, more recently, dendritic spine architecture, long-term potentiation and cognition \[[@R55]\]. Small-molecule ghrelin receptor agonists readily cross the blood brain barrier and elicit pro-cognitive effects in recognition and spatial learning and memory tests \[[@R55]\]. Due to its ubiquitous and diverse character, ghrelin is also of interest as a Zeitgeber referring to environmental cues that resets the body's circadian rhythm \[[@R56]\]. Meal times and the hormones associated with them are a subset of these internal cues and may help to synchronize circadian rhythms. Circadian rhythms are disrupted in AD \[[@R56]\]. In addition, declining circulating ghrelin has shown association with reduced appetite, reduced hippocampal neurogenesis and synaptic plasticity, weaker feeding-related zeitgeber, memory impairments, weight loss, and as aforementioned, disrupted circadian rhythms. All of these symptoms are associated with cognitive impairments and AD \[[@R56]\].

As shown in HIV− samples, ghrelin is inversely associated with BMI. However, in contrast with one published report on differences in several metabolic hormones and higher ghrelin levels in HIV+ versus HIV− controls, we observed no difference in mean ghrelin levels by HIV status \[[@R57]\].

GIP was not associated with cognitive test scores or HIV status, nor was it correlated with anthropometric measures. This may indicate agreement with the observed performance of GIP analogs versus native GIP in animal models in relation to cognition \[[@R27]\]. There is one published study on GIP in HIV infection, comparing those with *versus* without glucose intolerance \[[@R58]\]. GIP was associated with insulin secretion rates irrespective of glucose intolerance status. GIP has been associated with some cognitive outcome measures, primarily in animal models \[[@R24],[@R26],[@R27],[@R29]\]. Results of studies on GIP or other incretins and their analogs in cognition and AD have not been reported.

The influence of ART on cognition and overall health in HIV is inconsistent depending on the severity of cognitive outcome being assessed and age of the infected. Data suggest no difference in the proportion of individuals with HIV-associated cognitive disorder (HAND) in the pre- versus post-ART eras \[[@R59]\]; however, the prevalence of AIDS dementias, the most severe form of impairment, has fallen precipitously concurrent with optimization of medication regimens and better care overall \[[@R60]\]. As HIV-infected populations survive to older ages, they may be at risk for more severe cognitive impairments and age-related dementias, such as sporadic AD. This would be a new phenomenon, but is speculative at this time. ART may also have cardiovascular side effects, such as atherosclerosis \[[@R61],[@R62]\], DM \[[@R63]\] and hypertension \[[@R64]\], even in HIV-infected children \[[@R65]\]. These cardiovascular factors are related to risk for AD in populations without HIV infection; and cardiovascular risk factors are associated with worse cognition in persons with HIV \[[@R66],[@R67]\]. Thus, this begs the question of whether we are setting the stage for a form of iatrogenic AD in HIV-infected populations. While the positive influence of ART on cognition is clear \[[@R68]\]; there are several controversial studies providing data that suggest a negative influence \[[@R69]\]. Some studies show that discontinuing ART is associated with improved performance on cognitive tests \[[@R70]\]; and it has been speculated that certain ART regimens are deleterious for cognition \[[@R71]\]. Even so, alterations in gut tissue hormones, adipose tissue, adipose tissue distribution, adipose tissue hormones and/or lipid metabolism observed in HIV infection \[[@R31],[@R72]\], may also create an altered vascular, metabolic and/or hormonal milieu that is undesirable for the brain \[[@R73]\].

This is a large study of gut hormones and cognition in women with and without HIV infection. Strengths include the large multi-ethnic participant sample, and three gut hormone measures that have been evaluated to a limited extent in uninfected elderly samples in association with cognition. The primary limitations include a relatively few battery of cognitive tests, the existence of other unmeasured gut hormones of potential interest (e.g. GLP-1^55^), a cross-sectional study design and analysis, and the average age of participants being 39 years, making it perhaps difficult to detect influencers of cognitive function. In addition, due to multiple comparisons, and relatively high p-values, one must also consider risk for false discoveries. Our analyses were not adjusted for multiple comparisons. However, since this is one of the first reports of common gut hormones in relation to cognition in HIV, we chose an empirical data analysis approach. Not adjusting for multiple comparisons is preferable because it leads to fewer errors of interpretation and follows more closely, untainted natural observations of association \[[@R74]\]. Of note, this investigation of gut hormones and cognition represents a site-specific (Brooklyn only) sub-study of middle-aged women within the greater WIHS multi-center network. While WIHS has collected much information on a variety of factors and biomarkers for over 20 years as a result of its interdisciplinary nature, due to the exclusive availability of gut hormone measures at one point in time at one site, our analysis capacity to integrate all additional WIHS data is limited.

In summary, these data suggest the need for continued follow up of these women to determine mid-life and late-life effects of gut hormones, dietary factors and overweight and obesity on cognition and dementia in HIV.
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###### 

Cognitive tests administered in the WIHS and corresponding cognitive domains measured \[[@R41],[@R42]\].

  Cognitive Domain                        Test
  --------------------------------------- ---------------------------------------------------------------------------------------
  **Executive Function**                  Trails A, Trails B
  Stroop Interference \[[@R37],[@R38]\]   
  **Speed of Information Processing**     Symbol Digit Modalities Test (SDMT)[\*](#TFN1){ref-type="table-fn"} \[[@R39],[@R40]\]
  Stroop Color Naming and Reading         
  **Learning and Memory**                 Stroop Word Recall

The SDMT score is the number of correct items in 90 s, all other test scores are times with lesser time indicating better performance

###### 

Characteristics of WIHS participants with gut hormone measures.

                                                                  ALL (n=356)   HIV+ (n=248)    HIV− (n=108)                                            
  --------------------------------------------------------------- ------------- --------------- -------------- ------------------ ----- --------------- ---------
  Age                                                             356           38.9 (9.1)      248            40.0 (8.5)         108   36.5 (9.9)      \<0.001
  Race                                                            356                           248                               108                   0.46
  White                                                                         31 (8.7%)                      24 (9.7%)                7 (6.5%)        
  African American (AA)                                                         282 (79.1%)                    194 (78.2%)              88 (81.5%)      
  Non-white, non-AA Hispanic                                                    34 (9.6%)                      23 (9.3%)                11 (10.2%)      
  Other                                                                         9 (2.6%)                       7 (2.8%)                 2 (1.8%)        
  Highest education                                               355                           1194                              491                   0.571
  Grades 7--11                                                                  126 (35.5%)                    428 (35.9%)              158 (32.2%)     
  Completed HS                                                                  127 (35.8%)                    377 (31.6%)              162 (33.0%)     
  Some college                                                                  86 (24.2%)                     305 (25.5%)              131 (26.7%)     
  4 years degree                                                                14 (3.9%)                      62 (5.2%)                32 (6.5%)       
  attend/complete grad school                                                   2 (0.6%)                       22 (1.8%)                8 (1.6%)        
  CD4 count                                                                                     245            27,537 (140,597)                         
  Viral load                                                                                    246            518.5 (322.7)                            
  GIP (pg/ml)                                                     355           69.1 (87.4)     248            69.4 (82.5)        107   68.4 (98.3)     0.919
  Ghrelin (pg/ml)                                                 356           365.5 (223.6)   248            359.7 (316.6)      108   379.0 (367.9)   0.616
  Amylin (pg/ml)                                                  347           24.4 (51.4)     242            20.5 (20.2)        105   33.4 (87.9)     0.031
  Diabetes mellitus                                               313           15 (4.8%)       218            9 (4.1%)           95    6 (6.3%)        0.4
  BMI                                                             351           29.2 (7.9)      246            28.8 (7.3)         105   30.3 (9.1)      0.089
  WHR                                                             266           0.88 (0.08)     181            0.89 (0.08)        85    0.85 (0.07)     0.0001
  Marijuana use since last visit                                  356           64 (18.0%)      248            41 (16.5%)         108   23 (21.3%)      0.295
  Any indicator of hypertension[\*](#TFN2){ref-type="table-fn"}   356           129 (36.2%)     248            95 (38.3%)         108   34 (31.5%)      0.232
  Total Cholesterol                                               356           176.7 (26.39)   248            175.4 (37.3)       108   179.8 (34.1)    0.296

Either SBP\>=140, DBP\>=90, self-reported hypertension, or taking anti-hypertensive medication

###### 

Pearson correlations between anthropometric measures and gut hormones. The Women's Interagency HIV Study (WIHS).

                BMI   Waist    WHR                                                                                                             
  ------------- ----- -------- ---------- -------- ---------- ----- -------- ---------- -------- ---------- ----- -------- ---------- -------- ----------
  Log amylin    342   0.230    \<0.0001   0.229    \<0.0001   260   0.297    \<0.0001   0.276    \<0.0001   258   0.276    \<0.0001   0.276    \<0.0001
  Log ghrelin   351   −0.182   \<0.001    −0.181   \<0.001    268   −0.202   \<0.001    −0.2     0.001      266   −0.119   0.053      −0.116   0.06
  Log GIP       351   −0.028   0.602      −0.050   0.417      267   −0.046   0.455      −0.059   0.344      265   0.059    0.342      0.024    0.699

###### 

Gut-brain hormones in association with cognitive test score, by HIV infection status: the Women's Interagency HIV Study.

                                   All   HIV+                    HIV−                                                                         
  -------------------------------- ----- ----------------------- ------- ----- ----------------------- ------- ----- ------------------------ ---------
  **Trails A**                                                                                                                                
  **Log Amylin - Continuous**                                                                                                                 
   Model 1                         347   −2.85 (−4.90, −0.79)    0.007   242   −2.83 (−5.64, −0.04)    0.047   105   −2.03 (−4.83, 0.78)      0.156
   Model 2                         299   −2.44 (−4.74, −0.13)    0.038   211   −2.64 (−5.67, 0.40)     0.089   88    −1.78 (−5.10, 1.53)      0.287
  **Log GIP - Continuous**                                                                                                                    
   Model 1                         355   −1.28 (−2.98, 0.42)     0.141   248   −2.22 (−4.43, −0.02)    0.048   107   0.64 (−1.82, 3.10)       0.608
   Model 2                         307   −1.69 (−3.45, 0.06)     0.058   217   −2.41 (−4.67, −0.14)    0.037   90    0.24 (−2.42, 2.90)       0.859
  **Log ghrelin -- CATEGORICAL**                                                                                                              
   Model 1                                                                                                                                    
   Tertile 1 (low)                 356   0 (ref)                         248   0 (ref)                         108   0 (ref)                  
   Tertile 2                             0.38 (−3.59, 4.35)      0.851         3.42 (−1.64, 8.48)      0.184         −7.03 (−12.54, −1.51)    0.013
   Tertile 3                             −1.49 (−5.30, 2.33)     0.440         2.55 (−2.33, 7.43)      0.304         −10.7 (−15.94, −5.46)    \<0.001
   Model 2                                                                                                                                    
   Tertile 1 (low)                 308   0 (ref)                         217   0 (ref)                         91    0 (ref)                  
   Tertile 2                             0.52 (−3.69, 4.73)      0.808         3.23 (−2.17, 8.63)      0.239         −6.94 (−12.88, −0.99)    0.023
   Tertile 3                             −1.49 (−5.49, 2.52)     0.465         2.49 (−2.65, 7.63)      0.340         −10.5 (−16.03, −4.96)    \<0.001
  **Trails B**                                                                                                                                
  **Log Amylin - Continuous**                                                                                                                 
   Model 1                         346   −0.83 (−7.49, 5.84)     0.808   241   −3.11 (−12.41, 6.20)    0.511   105   3.03 (−5.40, 11.46)      0.478
   Model 2                         298   2.34 (−4.87, 9.55)      0.524   210   0.09 (−9.51, 9.69)      0.985   88    5.67 (−4.47, 15.82)      0.269
  **Log GIP - Continuous**                                                                                                                    
   Model 1                         354   −1.23 (−6.72, 4.26)     0.659   247   −4.05 (−11.33, 3.24)    0.275   107   4.14 (−3.25, 11.53)      0.269
   Model 2                         306   −2.32 (−7.81, 3.17)     0.406   216   −4.58 (−11.72, 2.57)    0.208   90    2.6 (−5.67, 10.87)       0.533
  **Log ghrelin - Categorical**                                                                                                               
   Model 1                                                                                                                                    
   Tertile 1 (low)                 355   0 (ref)                         247   0 (ref)                         108   0 (ref)                  
   Tertile 2                             3.84 (−8.94, 16.63)     0.555         10.8 (−5.83, 27.43)     0.202         −11.91 (−29.69, 5.87)    0.187
   Tertile 3                             0.9 (−11.35, 13.14)     0.886         8.9 (−7.06, 24.87)      0.273         −17.23 (−34.11, −0.34)   0.046
   Model 2                                                                                                                                    
   Tertile 1 (low)                 307   0 (ref)                         216   0 (ref)                         91    0 (ref)                  
   Tertile 2                             4.82 (−8.31, 17.95)     0.471         10.05 (−6.84, 26.94)    0.242         −10.13 (−30.09, 9.82)    0.316
   Tertile 3                             −0.64 (−13.08, 11.80)   0.919         6.3 (−9.71, 22.31)      0.439         −16.78 (−35.34, 1.78)    0.076
  **Digit Symbol**                                                                                                                            
  **Log Amylin - Continuous**                                                                                                                 
   Model 1                         342   0.86 (−0.64, 2.36)      0.259   238   1.09 (−0.87, 3.06)      0.274   104   0.07 (−2.27, 2.40)       0.956
   Model 2                         295   −0.01 (−1.62, 1.61)     0.993   208   0.43 (−1.61, 2.47)      0.678   87    −0.85 (−3.57, 1.87)      0.536
  **Log GIP - Continuous**                                                                                                                    
   Model 1                         350   0.16 (−1.08, 1.40)      0.802   244   0.64 (−0.92, 2.19)      0.423   106   −0.76 (−2.78, 1.26)      0.460
   Model 2                         303   0.46 (−0.78, 1.69)      0.466   214   0.57 (−0.96, 2.11)      0.463   89    0.13 (−2.03, 2.29)       0.908
  **Log ghrelin - Categorical**                                                                                                               
   Model 1                                                                                                                                    
   Tertile 1 (low)                 351   0 (ref)                         244   0 (ref)                         107   0 (ref)                  
   Tertile 2                             0.72 (−2.17, 3.61)      0.624         −1.18 (−4.76, 2.39)     0.515         5.46 (0.63, 10.29)       0.027
   Tertile 3                             1.3 (−1.49, 4.08)       0.360         0.1 (−3.37, 3.57)       0.954         3.98 (−0.56, 8.51)       0.085
   Model 2                                                                                                                                    
   Tertile 1 (low)                 304   0 (ref)                         214   0 (ref)                         90    0 (ref)                  
   Tertile 2                             1.03 (−1.92, 3.99)      0.492         −0.58 (−4.22, 3.06)     0.753         5.61 (0.44, 10.79)       0.034
   Tertile 3                             1.74 (−1.07, 4.55)      0.223         0.62 (−2.85, 4.10)      0.724         4.37 (−0.40, 9.13)       0.072
  **Stroop - Color naming time**                                                                                                              
  **Log Amylin - Continuous**                                                                                                                 
   Model 1                         307   −0.09 (−2.68, 2.49)     0.944   212   0.07 (−3.36, 3.50)      0.968   95    0.18 (−3.65, 4.00)       0.926
   Model 2                         268   −0.17 (−3.01, 2.68)     0.908   186   0.33 (−3.26, 3.91)      0.858   82    −0.5 (−5.04, 4.03)       0.826
  **Log GIP - Continuous**                                                                                                                    
   Model 1                         314   −2.04 (−4.10, 0.01)     0.052   217   −2.88 (−5.50, −0.26)    0.031   97    −0.35 (−3.57, 2.86)      0.828
   Model 2                         275   −1.79 (−3.88, 0.30)     0.093   191   −2.27 (−4.92, 0.38)     0.093   84    −0.68 (−3.99, 2.64)      0.686
  **Log ghrelin - Categorical**                                                                                                               
   Model 1                                                                                                                                    
  **Tertile 1 (Low)**              315   0 (ref)                         217   0 (ref)                         98    0 (ref)                  
   Tertile 2                             0.11 (−4.68, 4.90)      0.964         2.05 (−4.10, 8.19)      0.512         −4.1 (−11.38, 3.19)      0.267
   Tertile 3                             −5.48 (−10.07, −0.89)   0.019         −3.78 (−9.64, 2.09)     0.205         −9.45 (−16.47, −2.44)    0.009
   Model 2                                                                                                                                    
  **Tertile 1 (Low)**              276   0 (ref)                         191   0 (ref)                         85    0 (ref)                  
   Tertile 2                             −0.51 (−5.43, 4.42)     0.839         −0.66 (−7.00, 5.68)     0.838         −2.27 (−9.76, 5.22)      0.548
   Tertile 3                             −6.42 (−11.12, −1.72)   0.008         −5.8 (−11.79, 0.19)     0.057         −8.76 (−15.95, −1.57)    0.018
  **Stroop - Word Read time**                                                                                                                 
  **Log Amylin - Continuous**                                                                                                                 
   Model 1                         308   −0.38 (−2.53, 1.78)     0.731   213   −1.51 (−4.26, 1.24)     0.281   95    2.14 (−1.39, 5.67)       0.232
   Model 2                         269   −0.93 (−3.16, 1.31)     0.416   187   −1.88 (−4.58, 0.81)     0.169   82    2.32 (−1.74, 6.38)       0.259
  **Log GIP - Continuous**                                                                                                                    
   Model 1                         315   −0.41 (−2.13, 1.30)     0.636   218   −1.55 (−3.66, 0.55)     0.147   97    2.07 (−0.87, 5.01)       0.166
   Model 2                         276   −0.48 (−2.11, 1.16)     0.565   192   −1.29 (−3.28, 0.70)     0.203   84    1.37 (−1.56, 4.31)       0.355
  **Log ghrelin - Categorical**                                                                                                               
   Model 1                                                                                                                                    
   Tertile 1 (low)                 316   0 (ref)                         218   0 (ref)                         98    0 (ref)                  
   Tertile 2                             0.82 (−3.13, 4.78)      0.683         1.56 (−3.33, 6.44)      0.53          −0.96 (−7.81, 5.88)      0.781
   Tertile 3                             −5.46 (−9.26, −1.66)    0.005         −5.14 (−9.82, −0.45)    0.032         −6.28 (−12.87, 0.31)     0.062
   Model 2                                                                                                                                    
   Tertile 1 (low)                 277   0 (ref)                         192   0 (ref)                         85    0 (ref)                  
   Tertile 2                             1.32 (−2.51, 5.14)      0.498         0.32 (−4.40, 5.03)      0.894         3.21 (−3.46, 9.89)       0.341
   Tertile 3                             −5.36 (−9.02, −1.70)    0.004         −5.79 (−10.27, −1.31)   0.012         −4.91 (−11.32, 1.50)     0.132
  **Stroop - Interference time**                                                                                                              
  **Log Amylin - Continuous**                                                                                                                 
   Model 1                         302   −0.47 (−4.83, 3.89)     0.832   208   −1.19 (−6.79, 4.42)     0.677   94    −0.26 (−7.47, 6.96)      0.944
   Model 2                         265   −3.88 (−8.48, 0.73)     0.099   184   −2.93 (−8.50, 2.64)     0.301   81    −7.45 (−16.14, 1.22)     0.091
  **Log gip - Continuous**                                                                                                                    
   Model 1                         309   −2.59 (−6.04, 0.86)     0.140   213   −3.98 (−8.22, 0.27)     0.066   96    0.27 (−5.75, 6.29)       0.930
   Model 2                         272   −3.41 (−6.74, −0.07)    0.046   189   −4.07 (−8.11, −0.03)    0.049   83    −2.59 (−8.94, 3.76)      0.419
  **Log ghrelin - Categorical**                                                                                                               
   Model 1                                                                                                                                    
  **Tertile 1 (Low)**              310   0 (ref)                         213   0 (ref)                         97    0 (ref)                  
   Tertile 2                             1.91 (−6.23, 10.04)     0.645         5.83 (−4.21, 15.87)     0.254         −5.98 (−20.13, 8.16)     0.403
   Tertile 3                             −6.31 (−14.14, 1.52)    0.114         −4.55 (−14.20, 5.10)    0.353         −9.9 (−23.53, 3.73)      0.153
   Model 2                                                                                                                                    
  **Tertile 1 (Low)**              273   0 (ref)                         189   0 (ref)                         84    0 (ref)                  
   Tertile 2                             4.83 (−3.20, 12.87)     0.237         7.17 (−2.63, 16.97)     0.151         −0.3 (−15.40, 14.80)     0.969
   Tertile 3                             −4.47 (−12.18, 3.25)    0.255         −4.09 (−13.42, 5.24)    0.388         −5.19 (−19.71, 9.32)     0.478
